Clinoril
(sulindac)ApprovedSmall molecule
Sulindac is used to reduce pain, swelling, and stiffness caused by arthritis and other inflammatory conditions. It works by decreasing inflammation in the body to help relieve discomfort.[2] Clinoril is currently approved and in use across 12 indications[4].[1]
Clinoril is one of 250 small molecule programs targeting Rheumatic Disease. It is currently in Approved.
12
Indications
22
Total Trials
1
Active Trials
249
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
235 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Clinoril
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Idamycin
PfizerPhase 3
Novantrone
PfizerPhase 3
Xospata
AstellasPhase 3
Fludara
SanofiPhase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Vepesid
AAvyxa
Phase 3
Mylotarg
WWyeth-Lederle Vaccines
Phase 3
Vanflyta
Daiichi SankyoPhase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Colorectal Cancer3 trials
Breast Cancer2 trials
Familial adenomatous polyposis2 trials
Melanoma2 trials
12 more indications
Squamous Cell Carcinoma1 trial
Atorvastatin1 trial
Lung Cancer1 trial
IPMN1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
CLINORIL
NDA NDA017911
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Clinoril drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for sulindac. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details